- Home
- MDB vs BMRN Comparison
MDB vs BMRN Comparison
Compare MDB & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDB
- BMRN
- Stock Information
- Founded
- MDB 2007
- BMRN 1996
- Country
- MDB United States
- BMRN United States
- Employees
- MDB N/A
- BMRN N/A
- Industry
- MDB Computer Software: Prepackaged Software
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MDB Technology
- BMRN Health Care
- Exchange
- MDB Nasdaq
- BMRN Nasdaq
- Market Cap
- MDB 18.2B
- BMRN 16.0B
- IPO Year
- MDB 2017
- BMRN 1999
- Fundamental
- Price
- MDB $281.88
- BMRN $84.08
- Analyst Decision
- MDB Buy
- BMRN Buy
- Analyst Count
- MDB 27
- BMRN 21
- Target Price
- MDB $350.42
- BMRN $109.20
- AVG Volume (30 Days)
- MDB 1.5M
- BMRN 1.6M
- Earning Date
- MDB 08-29-2024
- BMRN 10-30-2024
- Dividend Yield
- MDB N/A
- BMRN N/A
- EPS Growth
- MDB N/A
- BMRN 154.24
- EPS
- MDB N/A
- BMRN 1.33
- Revenue
- MDB $1,819,610,000.00
- BMRN $2,588,398,000.00
- Revenue This Year
- MDB $15.92
- BMRN $18.10
- Revenue Next Year
- MDB $17.84
- BMRN $11.17
- P/E Ratio
- MDB N/A
- BMRN $63.00
- Revenue Growth
- MDB 22.37
- BMRN 15.83
- 52 Week Low
- MDB $212.74
- BMRN $73.68
- 52 Week High
- MDB $509.62
- BMRN $99.56
- Technical
- Relative Strength Index (RSI)
- MDB 61.28
- BMRN 36.71
- Support Level
- MDB $278.98
- BMRN $89.95
- Resistance Level
- MDB $297.77
- BMRN $92.81
- Average True Range (ATR)
- MDB 10.33
- BMRN 2.50
- MACD
- MDB 4.89
- BMRN -0.89
- Stochastic Oscillator
- MDB 75.97
- BMRN 3.15
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.